相关实验视频

Updated: May 6, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

多发性骨髓瘤的脏强化,溶解和血液静止移除疗法:表观遗传学和免疫调节随机对照试验的协议

Xiaoqi Sun¹, Yongming Zhou¹, Yujue Wang¹

¹Department of Hematology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, 110 Ganhe Road, Hongkou District, Shanghai, 200437, China, 86 13651784266.

JMIR research protocols

|March 11, 2026

概括

这项随机对照试验调查了KPR草药配方对多发性骨髓瘤 (MM) 中PHF19-EZH2-H3K27me3轴的影响. 该研究旨在改善MM患者的免疫微环境并恢复免疫功能.

科学领域:

综合性瘤学是一种综合性瘤学.
表观遗传学在表观遗传学中,表观遗传学是指表观遗传学.
免疫学免疫学免疫学

背景情况:

多发性骨髓瘤 (MM) 在中国传统医学 (TCM) 中表现为缺陷,和血液停滞.
在TCM的脏调,溶解和血液静止移除 (KPR) 方法中,针对MM病理.
PHF19/EZH2/H3K27me3表观遗传轴与MM免疫微环境失调有关.

研究的目的:

评估KPR草药配方与基于博特佐米布的疗法相结合是否能改善MM的免疫微环境.
通过PHF19-EZH2-H3K27me3表观遗传轴研究KPR配方的作用机制.
为将TCM纳入复发性或耐火性MM的基于证据的瘤学提供机制基础.

主要方法:

一个单中心,前性随机受控试验 (RCT) 与1:1:1分配给三个组.
治疗持续时间为12周,随访期为6个月.
主要结局:CD3+T细胞比率;次要结局:TCM综合征得分,疗效,血清,免疫球蛋白水平,M蛋白和成像.

主要成果:

招聘启动于2025年3月,截至2025年10月,已有41名患者注册.
数据收集预计将在2026年10月底结束;分析和结果预计在2027年.
目前还没有结果,因为数据分析尚未开始.

结论:

本RCT评估了一种针对MM患者PHF19-EZH2-H3K27me3轴的TCM配方.
它旨在建立一个基于生物标志物的框架,将TCM与免疫疗法整合起来.
为治疗不耐药的MM患者提供潜在的新策略.

关键词:

表观遗传调节表观遗传调节草药是一种草药.骨髓瘤多样性骨髓瘤多样性随机对照试验是随机对照试验.瘤免疫的微环境

更多相关视频

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.